Annals for Hospitalists Inpatient Notes - How We Treat Hyperglycemia in the Hospital
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
A76-year-old man with type 2 diabetes mellitus (T2D) is admitted for pneumonia. At home, he receives metformin and a dipeptidyl peptidase-4 (DPP-4) inhibitor. His body mass index is 24 kg/m, admission blood glucose (BG) level is 14.98 mmol/L (270 mg/dL), hemoglobin A1c level is 8.2%, and serum creatinine level is 123.76 μmol/L (1.4 mg/dL) (estimated glomerular filtration rate, 45 mL/min). The admitting team withdraws his oral agents and starts sliding-scale insulin (SSI) therapy. After 24 hours, his BG levels are consistently above 11.10mmol/L (>200mg/dL). Diabetes is a common diagnosis among hospitalized patients that is associated with poor outcomes if not appropriately treated (1). For most noncritically ill patients, we recommend a fasting and premeal BG target between 5.55 and 10 mmol/L (100 and 180 mg/dL). However, higher BG levels may be acceptable among patients who are terminally ill or who have severe comorbidities (1, 2). Among hospitalized patients, basal insulin analogues (for example, glargine, detemir, and degludec) given once daily and rapid-acting insulin (for example, lispro, aspart, and glulisine) given before meals are preferred over human insulin formulations (for example, neutral protamine Hagedorn and regular insulin). These newer insulin analogues allow for a more precise, separate coverage of basal and nutritional needs. There are also numerous noninsulin agents available for T2D, but a decision to continue such agents in the hospital varies highly in…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“DPP-4 inhibitors combined with low-dose basal insulin have been similarly effective to basal-bolus insulin and associated with less hypoglycemia and less treatment burden.1351,1354–1357,1359”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1351]
In the citing paper
“Oral DPP-4 inhibitors have been tested in RCTs in medical and surgical noncritically ill persons with mild hyperglycemia (admission glucose <180 mg/dL).1351,1354–1357”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1351]
In the citing paper
“For noncritically ill persons with T2D and mild-to-moderate hyperglycemia (ie, admission glycemia below 180 to 200 mg/dL),1266 the use of basal insulin plus correctional insulin (basal-plus regimen),108 or basal insulin with DPP-4 inhibitors, or DPP-4 inhibitors plus correctional insulin doses with rapid-acting insulin may provide equal glycemic control to basal-bolus insulin.1350–1352”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1351]
Citations
Cites
Umpierrez, G. E., Hellman, R., Korytkowski, M. T., Kosiborod, M., Maynard, G. A., Montori, V. M., Seley, J. J., & Van den Berghe, G. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2098 · Cited by 1,126
Self-citationManagement of diabetes and hyperglycaemia in the hospital
Pasquel, F. J., Lansang, M. C., Dhatariya, K., & Umpierrez, G. E. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30381-8 · Cited by 329
Self-citationUmpierrez, G. E., Smiley, D., Hermayer, K., Khan, A., Olson, D. E., Newton, C., Jacobs, S., Rizzo, M., Peng, L., Reyes, D., et al. (2013) · Diabetes Care · doi:10.2337/dc12-1988 · Cited by 222
Self-citationPasquel, F. J., Gianchandani, R., Rubin, D. J., Dungan, K. M., Anzola, I., Gomez, P. C., Peng, L., Hodish, I., Bodnar, T., Wesorick, D., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30402-8 · Cited by 168 · cited 1×
“6 units/kg per day, a DPP-4 inhibitor and basal insulin combination is as effective as basal–bolus insulin therapy (4).”
BackgroundSelf-citation
Cited by
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Self-citationBramante, C. T., Buse, J. B., Liebovitz, D., Nicklas, J. M., Puskarich, M. A., Cohen, K., Belani, H., Anderson, B., Huling, J. D., Tignanelli, C. J., et al. (2022) · medRxiv · doi:10.1101/2022.12.21.22283753 · Cited by 41
Galindo, R. J., Dhatariya, K., Peralta, F. G., & Umpierrez, G. E. (2022) · Current Diabetes Reports · doi:10.1007/s11892-022-01464-1 · Cited by 36
Self-citationAdvances in the management of hyperglycaemia and diabetes mellitus during hospitalization
Idrees, T., Castro-Revoredo, I., Dhatariya, K., Hernandez, L., & Umpierrez, G. E. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01157-1 · Cited by 25
“Examples of individualization include avoiding tight control in a person with multiple comorbidities or allowing patients well-controlled with excellent time in range on continuous subcutaneous insulin infusions (pumps) to continue with tight glycaemic control if they wish and can do so 32,33 .”
InfluentialSelf-citationManagement of Hyperglycemia in Hospitalized Patients
Gianchandani, R. Y., Wei, M., & Demidowich, A. P. (2024) · Annals of Internal Medicine · doi:10.7326/annals-24-02754 · Cited by 12
Metadata
- Authors
- Pasquel, F. J., & Umpierrez, G. E.
- Affiliations
- Emory University (US)
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2021-08
- Volume
- 174
- Issue
- 8
- Pages
- HO2-HO4
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W3193449096
- Cited by
- 9
- References
- 4
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 1 · 2023: 2 · 2022: 4
- FWCI
- 1.31
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- hyperglycemia, hospitalized patients, glycemic control, diabetes management, intensive care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.